SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2024.
First Quarter 2024 Financial Highlights
Recent Operational Highlights
"During the first quarter of 2024, we were very pleased with the continued momentum in our core markets that enabled record unit volumes as well as strong new account openings," said Quentin Blackford, president and chief executive officer of iRhythm. "First quarter revenue growth of 18.4% year-over-year was driven by sustained growth in our existing accounts but also significant contribution from accounts opened within the past twelve months. We have been very encouraged with the growing traction within the primary care channel, highlighting Zio's value proposition as a workflow efficiency tool to expand ambulatory cardiac monitoring capacity within large care networks. When combined with progress that we are making with electronic health integration and emerging clinical evidence on the potential for EKG data to provide future clinical insights, we could not be more excited about our positioning to create significant value for patients, clinicians, healthcare systems, and stakeholders."
First Quarter Financial Results
Revenue for the first quarter of 2024 was $131.9 million, up 18.4% from $111.4 million during the same period in 2023. The increase was driven by growth in demand for Zio services.
Gross profit for the first quarter of 2024 was $87.5 million, up 15.6% from $75.7 million during the same period in 2023, while gross margin was 66.3%, down from 67.9% during the same period in 2023. The increase in gross profit was primarily due to increased volume of Zio services provided due to higher demand. The decrease in gross margin was primarily due to accelerated recognition of the cost of our legacy Zio XT components associated with our ongoing Zio monitor commercial launch as well as costs related to scaling and training newly onboarded clinical cardiac technicians at our San Francisco IDTF center of excellence.
Operating expenses for the first quarter of 2024 were $125.7 million, compared to $115.2 million for the same period in 2023. Adjusted operating expenses for the first quarter of 2024 were $125.7 million, compared to $109.5 million during the same period in 2023. This increase in adjusted operating expenses resulted primarily from increased headcount-related and third-party costs to support growth in operations and the further development, enhancement, and functionality of our current and future product offerings.
Net loss for the first quarter of 2024 was $45.7 million, or a diluted loss of $1.47 per share, compared with net loss of $39.1 million, or a diluted loss of $1.29 per share, for the same period in 2023. Adjusted net loss for the first quarter of 2024 was $38.1 million, or a diluted loss of $1.23 per share, compared with an adjusted net loss of $33.4 million, or a diluted loss of $1.10 per share, for the same period in 2023.
Unrestricted cash, cash equivalents, and marketable securities were $569.1 million as of March 31, 2024.
2024 Annual Guidance
iRhythm projects revenue for the full year 2024 to grow approximately 17% to 19% compared to prior year results, ranging from approximately $578 million to $588 million. Gross margin for the full year 2024 is expected to range from 68% to 69% and adjusted EBITDA margin for the full year 2024 is expected to range from approximately 3% to 4% of revenues.
Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
Use of Non-GAAP Financial Measures
We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted net loss, adjusted net loss per share and adjusted operating expenses. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted operating expenses and adjusted EBITDA estimates for full year 2024 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted operating expenses and adjusted EBITDA estimates is not available without unreasonable effort.
Adjusted EBITDA excludes non-cash operating charges for stock-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, impairment and restructuring charges, loss on extinguishment of debt, and business transformation costs.
We exclude the following items from non-GAAP financial measures for adjusted net loss, adjusted net loss per share and adjusted operating expenses:
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, anticipated productivity improvements and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including those on the Form 10-Q expected to be filed on or about May 2, 2024. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.
Investor Relations Contact
Stephanie Zhadkevich
(919) 452-5430
This email address is being protected from spambots. You need JavaScript enabled to view it.
iRhythm Media Contact
Saige Smith
(262) 289-7065
This email address is being protected from spambots. You need JavaScript enabled to view it.
| IRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Balance Sheets (unaudited) (In thousands, except par value) | |||||||
| March 31, 2024 | December 31, 2023 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 520,421 | $ | 36,173 | |||
| Marketable securities | 48,671 | 97,591 | |||||
| Accounts receivable, net | 89,712 | 61,484 | |||||
| Inventory | 14,873 | 13,973 | |||||
| Prepaid expenses and other current assets | 13,778 | 21,591 | |||||
| Total current assets | 687,455 | 230,812 | |||||
| Property and equipment, net | 112,274 | 104,114 | |||||
| Operating lease right-of-use assets | 48,073 | 49,317 | |||||
| Restricted cash, long-term | 8,358 | — | |||||
| Goodwill | 862 | 862 | |||||
| Other assets | 52,733 | 48,039 | |||||
| Total assets | $ | 909,755 | $ | 433,144 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 8,440 | $ | 5,543 | |||
| Accrued liabilities | 70,044 | 83,362 | |||||
| Deferred revenue | 3,068 | 3,306 | |||||
| Operating lease liabilities, current portion | 15,289 | 15,159 | |||||
| Total current liabilities | 96,841 | 107,370 | |||||
| Long-term senior convertible notes | 644,076 | — | |||||
| Debt, noncurrent portion | — | 34,950 | |||||
| Other noncurrent liabilities | 908 | 1,012 | |||||
| Operating lease liabilities, noncurrent portion | 77,640 | 79,715 | |||||
| Total liabilities | 819,465 | 223,047 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock, $0.001 par value – 5,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023 | — | — | |||||
| Common stock, $0.001 par value – 100,000 shares authorized; 31,326 shares issued and 31,097 shares outstanding at March 31, 2024, respectively; and 30,954 shares issued and outstanding at December 31, 2023 | 31 | 31 | |||||
| Additional paid-in capital | 806,621 | 855,784 | |||||
| Accumulated other comprehensive loss | (89 | ) | (112 | ) | |||
| Accumulated deficit | (691,273 | ) | (645,606 | ) | |||
| Treasury stock, at cost; 229 and 0 shares at March 31, 2024 and December 31, 2023, respectively | (25,000 | ) | — | ||||
| Total stockholders’ equity | 90,290 | 210,097 | |||||
| Total liabilities and stockholders’ equity | $ | 909,755 | $ | 433,144 | |||
| IRHYTHM TECHNOLOGIES, INC. Condensed Consolidated Statements of Operations (unaudited) (In thousands, except per share data) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenue, net | $ | 131,929 | $ | 111,436 | ||||
| Cost of revenue | 44,413 | 35,755 | ||||||
| Gross profit | 87,516 | 75,681 | ||||||
| Operating expenses: | ||||||||
| Research and development | 16,994 | 14,842 | ||||||
| Selling, general and administrative | 108,660 | 100,343 | ||||||
| Total operating expenses | 125,654 | 115,185 | ||||||
| Loss from operations | (38,138 | ) | (39,504 | ) | ||||
| Interest expense | (2,860 | ) | (950 | ) | ||||
| Interest and other income, net | 2,952 | 1,432 | ||||||
| Loss on extinguishment of debt | (7,589 | ) | — | |||||
| Loss before income taxes | (45,635 | ) | (39,022 | ) | ||||
| Income tax provision | 32 | 87 | ||||||
| Net loss | $ | (45,667 | ) | $ | (39,109 | ) | ||
| Net loss per common share, basic and diluted | $ | (1.47 | ) | $ | (1.29 | ) | ||
| Weighted-average shares, basic and diluted | 31,033 | 30,297 | ||||||
| IRHYTHM TECHNOLOGIES, INC. Reconciliation of GAAP to Non-GAAP Financial Information (unaudited) (in thousands, except per share data) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Adjusted EBITDA reconciliation | ||||||||
| Net loss | $ | (45,667 | ) | $ | (39,109 | ) | ||
| Interest expense | 2,860 | 950 | ||||||
| Interest income | (3,057 | ) | (1,434 | ) | ||||
| Income tax provision | 32 | 87 | ||||||
| Depreciation and amortization | 5,131 | 3,576 | ||||||
| Stock-based compensation | 20,991 | 18,251 | ||||||
| Business transformation costs | — | 5,686 | ||||||
| Loss on extinguishment of debt | 7,589 | — | ||||||
| Adjusted EBITDA | $ | (12,121 | ) | $ | (11,993 | ) | ||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Adjusted net loss reconciliation | ||||||||
| Net loss, as reported | $ | (45,667 | ) | $ | (39,109 | ) | ||
| Business transformation costs | — | 5,686 | ||||||
| Loss on extinguishment of debt | 7,589 | — | ||||||
| Adjusted net loss | $ | (38,078 | ) | $ | (33,423 | ) | ||
| Adjusted net loss per share reconciliation | ||||||||
| Net loss per share, as reported | $ | (1.47 | ) | $ | (1.29 | ) | ||
| Business transformation costs per share | — | 0.19 | ||||||
| Loss on extinguishment of debt | 0.24 | — | ||||||
| Adjusted net loss per share | $ | (1.23 | ) | $ | (1.10 | ) | ||
| Weighted-average shares, basic and diluted | 31,033 | 30,297 | ||||||
| Adjusted operating expense reconciliation | ||||||||
| Operating expense, as reported | $ | 125,654 | $ | 115,185 | ||||
| Business transformation costs | — | (5,686 | ) | |||||
| Adjusted operating expense | $ | 125,654 | $ | 109,499 | ||||
| Last Trade: | US$77.38 |
| Daily Change: | 3.39 4.58 |
| Daily Volume: | 53,051 |
| Market Cap: | US$2.420B |
October 30, 2024 October 30, 2024 October 21, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
